JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 42(2008) N 5 p. 806-813;
T.S. Nepomnyashchikh, S.N. Shchelkunov1

Poxviral immunomodulating proteins: New tools for immunity correction

Vector State Research Center of Virology and Biotechnology, Federal Service for Surveillance in Consumer Rights Protection and Human Well-Being, Koltsovo, Novosibirsk region, 630559, Russia
Received - 2008-04-01; Accepted - 2008-04-10

Many viral proteins are presently known to modulate the protective responses in the host organism. The genomes of Poxviridae have the greatest number of genes coding for proteins that suppress the inflammatory response, action of interferons, immune response, and other protective reactions. This review considers the poxviral immunomodulating proteins: TNF-, chemokine-, and complement-binding proteins and serine protease inhibitors. These proteins demonstrate therapeutic effects in animal models of autoimmune and inflammatory conditions. The applicability of poxviral immunomodulating proteins to treatment of autoimmune and inflammatory disorders in humans is discussed.

Poxvirus, complement-binding protein, serine protease inhibitor, chemokine-binding protein, tumor necrosis factor-binding protein



JMB-FOOTER RAS-JOURNALS